HAVCR2 and glioma: Using orthogonal strategies of high-dimensional immunofluorescence multiplexing and sc-Seq within the TME, we discovered that targeting TIM3 could potentially benefit patients with BRAF fusion PA and, more broadly, non-high-grade MAPK-activated gliomas.